首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EBI3 |
| Uniprot No | Q14213 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-229aa |
| 氨基酸序列 | RKGPPAALTLPRVQCRASRYPIAVDCSWTLPPAPNSTSPV SFIATYRL GMAARGHSWPCLQQTPTSTSCTITDVQLFSMAPYVLNVTAVHPWGSSSSF VP FITEHIIKPDPPEGVRLSPLAERQLQVQWEPPGSWPFPEIFSLKYW IRYKRQGAARFHRV GPIEATSFILRAVRPRARYYVQVAAQDLTDYGEL SDWSLPATATMSLGK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇与 **EBI3重组蛋白** 相关的文献摘要信息，供参考：
---
1. **文献名称**：*IL-27. a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells*
**作者**：Pflanz, S. et al. (2002)
**摘要**：该研究首次报道了 **EBI3重组蛋白** 与IL-12家族的p28亚基形成异源二聚体细胞因子IL-27.揭示了其通过激活STAT信号通路促进初始CD4+ T细胞增殖的功能。
---
2. **文献名称**：*Cloning of a cDNA encoding the Epstein-Barr virus-encoded protein EBI3 and characterization of its expression*
**作者**：Devergne, O. et al. (1997)
**摘要**：研究通过克隆EB病毒诱导的 **EBI3基因**，发现其在EBV感染的B细胞中高表达，并成功利用重组蛋白技术表达EBI3.提示其可能在病毒介导的免疫逃逸中发挥作用。
---
3. **文献名称**：*The inhibitory cytokine IL-35 contributes to regulatory T-cell function*
**作者**：Collison, L.W. & Vignali, D.A. (2008)
**摘要**：研究发现 **EBI3重组蛋白** 与IL-12α亚基(p35)结合形成新型抑制性细胞因子IL-35.并证明其在调节性T细胞(Treg)介导的免疫抑制中起关键作用。
---
4. **文献名称**：*EBI3 deficiency leads to diminished T helper cell responses and enhanced susceptibility to mycobacterial infection*
**作者**：Wang, T. et al. (2013)
**摘要**：通过构建EBI3基因敲除小鼠模型，结合重组蛋白回补实验，证明EBI3通过调控IL-27/IL-35平衡影响Th1/Th2免疫应答，并参与宿主对分枝杆菌感染的防御机制。
---
以上文献涵盖了EBI3重组蛋白的结构解析、功能研究及其在免疫调节和疾病中的作用。如需具体期刊或页码，可进一步补充关键词检索。
EBI3 (Epstein-Barr virus-induced gene 3) is a protein subunit initially identified in Epstein-Barr virus-infected B lymphocytes. It belongs to the interleukin-12 (IL-12) cytokine family and functions as a component of heterodimeric cytokines. EBI3 lacks intrinsic signaling capacity but pairs with specific partners to form bioactive cytokines. Notably, it combines with p28 to form IL-27 and associates with p35 to create IL-35. both of which play critical roles in immune regulation. IL-27 exhibits pro-inflammatory and anti-inflammatory properties, influencing T-cell differentiation and limiting excessive immune responses. In contrast, IL-35 is immunosuppressive, promoting regulatory T-cell (Treg) expansion and dampening effector T-cell activity.
Recombinant EBI3 protein is engineered using expression systems (e.g., mammalian, bacterial) to study its structural and functional roles in cytokine complexes. Researchers utilize it to dissect receptor binding mechanisms, signaling pathways, and immunomodulatory effects in diseases like autoimmune disorders, infections, and cancer. For example, IL-27/EBI3 interactions are explored for their dual role in tumor immunity—enhancing anti-tumor responses while potentially supporting immune evasion. Similarly, IL-35/EBI3 is investigated as a therapeutic target in chronic inflammation.
EBI3’s involvement in balancing immune activation and tolerance makes it a focal point for drug development. Recombinant EBI3 also aids in producing antibodies or inhibitors to modulate cytokine activity. Challenges include understanding context-dependent effects, as EBI3-containing cytokines can exhibit opposing functions in different microenvironments. Ongoing studies aim to clarify its therapeutic potential, particularly in diseases where immune dysregulation is central.
×
